Ishita Drugs & Industries Ltd Upgraded to Sell on Technical Improvements Despite Flat Financials

Quality Assessment: Weak Fundamentals Persist

Despite the upgrade in rating, Ishita Drugs’ fundamental quality remains underwhelming. The company’s long-term Return on Equity (ROE) averages a modest 8.40%, signalling limited profitability relative to shareholder equity. Over the past five years, net sales have grown at a sluggish compound annual growth rate (CAGR) of 4.99%, while operating profit has expanded at a slightly better but still modest 7.71% CAGR. These figures indicate a lack of robust growth momentum in a sector where innovation and expansion are critical.

Moreover, the company’s ability to service debt is concerning. The average EBIT to interest coverage ratio stands at a weak 0.85, suggesting that operating earnings are insufficient to comfortably cover interest expenses. This financial strain is further reflected in the latest quarterly results for Q2 FY25-26, which showed flat performance with operating cash flow at a low of ₹-3.64 crores and PBDIT barely positive at ₹0.19 crores. Profit before tax excluding other income also remained subdued at ₹0.15 crores, underscoring operational challenges.

Valuation: Attractive Yet Reflective of Risks

On the valuation front, Ishita Drugs presents a mixed picture. The stock trades at a Price to Book (P/B) ratio of 2.2, which is considered attractive relative to its peers and historical averages in the Pharmaceuticals & Biotechnology sector. This valuation suggests that the market is pricing in the company’s weak fundamentals but also recognising some latent value. The company’s ROE of 9% supports this fair valuation, indicating that investors are not overpaying for the stock despite its challenges.

Additionally, the Price/Earnings to Growth (PEG) ratio stands at 0.8, signalling that the stock may be undervalued relative to its earnings growth potential. Over the past year, while the stock price declined by 9.60%, the company’s profits rose by 23%, highlighting a disconnect between market pricing and earnings performance. This divergence may offer a value opportunity for investors willing to look beyond short-term volatility.

Financial Trend: Flat Quarterly Performance Amidst Long-Term Underperformance

The company’s recent financial trend remains flat, with Q2 FY25-26 results showing minimal growth or improvement. Operating cash flows have hit a low point, and profitability metrics remain near their lowest levels in recent quarters. This stagnation is a key factor weighing on the company’s long-term outlook.

In terms of market returns, Ishita Drugs has underperformed significantly over the last year. While the BSE500 index generated a positive return of 5.24%, the stock declined by 9.60%. This underperformance extends to the year-to-date period as well, where the stock’s return of -13.45% contrasts sharply with the Sensex’s 8.39% gain. However, over longer horizons, Ishita Drugs has outpaced the Sensex, delivering a 54.44% return over three years and an impressive 142.42% over five years, indicating some resilience in the broader timeframe.

Technicals: Key Driver Behind Upgrade

The primary catalyst for the upgrade from Strong Sell to Sell is the improvement in technical indicators. The technical grade shifted from mildly bearish to sideways, signalling a stabilisation in price momentum. Key technical metrics reveal a nuanced picture:

• MACD: Weekly readings have turned mildly bullish, although monthly signals remain mildly bearish, suggesting short-term momentum is improving but longer-term caution persists.


• RSI: Both weekly and monthly Relative Strength Index readings show no clear signal, indicating neither overbought nor oversold conditions.


• Bollinger Bands: Weekly bands are bullish, reflecting increased price volatility to the upside, while monthly bands remain sideways, consistent with consolidation.


• Moving Averages: Daily averages remain mildly bearish, indicating some short-term resistance to upward price movement.


• KST (Know Sure Thing): Weekly KST is mildly bullish, but monthly KST remains mildly bearish, mirroring the MACD pattern.


• Dow Theory: Both weekly and monthly trends are mildly bullish, suggesting a nascent uptrend in price action.

These mixed but improving technical signals have encouraged a more positive market stance, reflected in the stock’s 5.26% gain on the day of the rating change, with the price rising from ₹76.00 to ₹80.00 and intraday highs touching ₹90.85. The 52-week price range of ₹62.35 to ₹99.64 provides context for current valuation levels.

Market Capitalisation and Shareholding

Ishita Drugs holds a Market Cap Grade of 4, indicating a relatively small market capitalisation within its sector. The majority of shares are held by non-institutional investors, which can contribute to higher volatility and less predictable trading patterns. This ownership structure may also impact liquidity and investor confidence.

Comparative Performance and Outlook

While the stock’s short-term performance has been disappointing, its longer-term returns have been robust. Over the past decade, Ishita Drugs has delivered a remarkable 317.75% return compared to the Sensex’s 224.76%, highlighting the company’s potential to generate value over extended periods. However, the recent flat financial results and weak debt servicing capacity temper enthusiasm.

Investors should weigh the improved technical outlook against the company’s fundamental challenges. The sideways technical trend and mildly bullish weekly indicators suggest a possible base formation, but the absence of strong fundamental catalysts means caution remains warranted.

Conclusion: A Cautious Upgrade Reflecting Technical Stabilisation

The upgrade of Ishita Drugs & Industries Ltd from Strong Sell to Sell reflects a nuanced reassessment of the company’s prospects. While fundamental and financial metrics remain weak, the technical landscape has improved sufficiently to warrant a less negative stance. The stock’s attractive valuation and improving profit growth contrast with flat quarterly results and weak debt coverage, creating a complex investment case.

For investors, this rating change signals a potential opportunity to monitor the stock for further technical confirmation before considering entry. The company’s long-term growth and financial health require improvement to justify a more positive rating. Until then, the Sell rating advises caution, recognising the stock’s current stabilisation but ongoing risks.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Today